Search the Newsreel

Fairmount Funds holds 16.5% of Crescent Biopharma (CBIO) after July 2026 deal

Fairmount Funds Management LLC and its affiliates, including Fairmount Healthcare Fund II L.P., now beneficially own 16.50% of Crescent Biopharma (CBIO), totaling 6,593,385 Ordinary Shares as of July 16, 2026. This increased stake follows the purchase of 853,450 Ordinary Shares and Pre-Funded Warrants for …

Fairmount Healthcare Fund II LP acquires 853,450 Crescent Biopharma shares for $12.38 million

Fairmount Healthcare Fund II LP has acquired 853,450 ordinary shares of Crescent Biopharma at $14.5 each, increasing its total stake to 3,601,316 shares. Additionally, the fund purchased 525,897 pre-funded warrants at the same price, bringing its warrant position to 2,294,037. Tomas Kiselak, managing member …

Fairmount Funds' $12 Million Bet on Crescent Biopharma: A Strong Signal Amidst Volatility

Fairmount Funds Management, a major stakeholder and director of Crescent Biopharma (CBIO), recently invested over

Insider fund at Crescent Biopharma (NASDAQ: CBIO) buys 1.38M shares, warrants

Fairmount Healthcare Fund II L.P., an entity linked to Crescent Biopharma (NASDAQ: CBIO), recently acquired 853,450 ordinary shares and 525,897 pre-funded warrants, totaling 1.38 million share equivalents. These transactions, executed on July 16, 2026, increased Fairmount's indirect holdings to over 3.6 million ordinary shares …

Crescent Biopharma (CBIO) Jefferies Global Healthcare Conference 2026 Summary

Crescent Biopharma (CBIO) presented at the Jefferies Global Healthcare Conference 2026, highlighting strong clinical data for HARMONi-6, validating PD-1/VEGF bispecifics, and discussing critical trial design strategies. The company provided updates on its pipeline, focusing on CR-001 as a best-in-class backbone therapy and its partnership …

Crescent Biopharma (CBIO) Proxy filing Summary

Crescent Biopharma (CBIO) has released a summary of its proxy filing ahead of its Annual General Meeting on June 2, 2026. Key proposals include the election of two Class II directors, ratification of PricewaterhouseCoopers LLP as auditor, and advisory votes on executive compensation and …

Crescent Biopharma Offering Closes With 9.4M Shares, Warrants

Crescent Biopharma (CBIO) announced the closing of its underwritten public offering, which included 9,387,896 ordinary shares and pre-funded warrants for up to 525,897 ordinary shares. The offering, priced at $14.50 per ordinary share and $14.499 per pre-funded warrant, generated approximately $143.7 million in gross …

Form 424B5 CRESCENT BIOPHARMA, INC.

Crescent Biopharma, Inc. is offering 8,094,793 ordinary shares and 525,897 pre-funded warrants, with an aim to raise approximately $115.9 million in net proceeds to fund clinical development of its product candidates CR-001, CR-002, and CR-003, as well as for research and development and general …

Crescent Biopharma (Nasdaq: CBIO) prices $125.0 million stock and warrant sale

Crescent Biopharma (Nasdaq: CBIO) has priced a public offering of ordinary shares and pre-funded warrants, aiming to raise approximately $125.0 million in gross proceeds. The offering includes 8,094,793 ordinary shares at $14.50 each and 525,897 pre-funded warrants at $14.499 each. The company expects net …

CRESCENT BIOPHARMA, INC. SEC Filing (Jul 13, 2026)

Crescent Biopharma Shows Strength as Shares Rise Nearly 3% - Cup and Handle

Rainbows and Unicorns: Crescent Biopharma, Inc. (NASDAQ:CBIO) Analysts Just Became A Lot More Optimistic

Crescent Biopharma (CBIO) Posts US$10.8m Q4 Revenue Against Heavy Losses Challenging Bullish Narratives

Crescent Biopharma, Inc. (CBIO) stock price, news, quote and history

Crescent Biopharma (CBIO) Stock Forecast & Price Target

Crescent Biopharma (CBIO) Stock Price, News & Analysis

Should I buy Crescent Biopharma, Inc. (CBIO)